NCT01038388View on ClinicalTrials.gov

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 15, 2010

Primary Completion Date

August 5, 2021

Study Completion Date

August 5, 2021

Conditions

Multiple Myeloma

Interventions

DRUG

Bortezomib

1.3mg/m² given IV or subcutaneously

DRUG

Lenalidomide

25 mg given PO

DRUG

Dexamethasone

20 mg given PO

DRUG

Vorinostat

100, 200, or 300 mg given PO

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Emory University

OTHER